Bank of America downgraded Sun Pharma stock to ‘underperform’ from ‘neutral’, citing risks to premium valuations and slower speciality execution. The brokerage cut its target price, flagging concerns over Ilumya’s Medicare exposure, pricing pressures, and limited earnings visibility despite strong initial performance.
Adani’s Cemindia is said to near up to $524 million share sale
Adani Group-backed Cemindia Projects, formerly known as ITD Cementation India, is preparing to launch a qualified institutional placement (QIP) to raise up to Rs 5,000
August 26, 2026